Lixin Li received her Medical Degree in 1989 and obtained her PhD degree in 2002. Dr. Li did her Postdoctoral training in the department of Physiology at University of Toronto. She is the assistant professor in physician assistant program at Central Michigan University. Her research interests have been focused on the underlying mechanism of pathogenesis of type 2 diabetes with a specific focus on β-cell dysfunction as well as the molecular mechanism of obesity associated insulin resistance. Her major research interest also include the proglucagon-derived peptides, glucagon-like peptide-1 (GLP-1) and its role in regulating growth and function of the beta-cell. Her current research is studying the underlying physiological and molecular mechanisms of GLP-1 included in weight loss


Obesity is a risk factor for type 2 diabetes, coronary heart disease, and stroke. Glucagon like peptide -1 (GLP-1) is synthesized by the L cells of ileal mucosa and is released after nutrients ingestion. GLP-1 potentiates glucose-induced insulin secretion. Liraglutide, a full agonist of the GLP-1 receptor, has long-lasting. Although research has found the protective effect of GLP-1 agonist on weight gain in type 2 diabetes, the mechanisms is not clear. Brown adipose tissue plays a major role in the control of energy balance in rodents, whether GLP-1 activate the brown fat activity or differentiation has not been studied. In this study, we examine the potential protective effect of liraglutide on high fat high sucrose (HFHS) diet induced obesity. Four groups of mice were fed with regular chow or HFHS diet, liraglutide (100µg /kg) or vehicle (PBS) were injected daily for five weeks. The mice body weight increased by 12% in chow diet group and increased by 32.9% in HFHS diet group after 5 weeks. Liraglutide significantly attenuate the weight gain in both chow diet (increased by 8%) and HFHS diet (increased by 16% ), which is associated with significantly reduced epididymal fat mass. Reduce food intake was observed in liraglutide treated mice comparing with control groups, however, liraglutide fail to suppress food consumption after three weeks’ treatment. Liraglutide increased the mRNA level of brown fat specific genes including peroxisome proliferator-activated receptor gamma PPAR-ϒ (PPAR-γ), uncoupling protein-1 (UCP-1), and cell death activator-a (Cidea) in skeletal muscle tissue from HFHS diet fed mice. These data indicate that protective effects of liraglutide on diet induced obesity may act through multiple mechanisms, including suppressing appetite, and increasing energy expenditure. Liraglutide is a potential therapy for obesity and obesity related metabolic disorders